109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
一例罕见的化疗联合免疫治疗用于双原发甲胎蛋白阳性胃癌和同步小细胞肺癌的病例
Authors Bian J , Sun Y , Zhang T
Received 1 July 2025
Accepted for publication 25 October 2025
Published 15 November 2025 Volume 2025:17 Pages 2785—2791
DOI https://doi.org/10.2147/CMAR.S548762
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Yong Teng
Jiangyu Bian, Yuxing Sun, Tong Zhang
Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, People’s Republic of China
Correspondence: Tong Zhang, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1, Xiyuan Playground, Haidian District, Beijing, 100091, People’s Republic of China, Tel +86-010-62835438, Email ashtray7654@126.com
Background: Alpha-fetoprotein-positive gastric cancer (AFPGC) is a rare subtype of gastric cancer characterized by high invasiveness and extremely poor prognosis. According to relevant studies, the median overall survival of such patients is significantly shorter than that of AFP-negative gastric cancer patients (14 months vs 40 months). Small cell lung cancer (SCLC), the most malignant type of lung cancer, has a median survival time of only 8– 12 months in patients with extensive disease. To date, there have been no reported cases of dual primary cancers involving both AFPGC and SCLC, and the therapeutic role of immunotherapy in such dual primary tumors remains unclear.
Case Presentation: This paper reports a case of a 72-year-old male patient who was diagnosed via imaging and pathology as having concurrent AFPGC (moderately to poorly differentiated adenocarcinoma, PD-L1 positive, Tumor mutation burden(TMB) 10.03Muts/Mb, PD-L1 Combined Positive Score (CPS)< 1) combined with primary extensive-stage SCLC. The patient received CAPEOX regimen (capecitabine plus oxaliplatin) combined with tislelizumab therapy. After 4 cycles, partial response (PR) was observed in the gastric lymph nodes, and stable disease (SD) was noted in the pulmonary lesions. Following pathological confirmation of dual primary cancers, treatment continued with the original regimen, followed by maintenance therapy with tegafur gimeracil oteracil potassium capsule (teysuno) plus tislelizumab. During treatment, serum AFP levels decreased from baseline 502 μg/L to 1.56 μg/L. Both primary tumor lesions remained stably controlled for over 33 months, and the patient currently tolerates treatment well with an Eastern Cooperative Oncology Group (ECOG) performance status of 0.
Conclusion: Through the long-term treatment course of this case, we validated the therapeutic efficacy of chemotherapy combined with immunotherapy (CAPEOX plus tislelizumab) for the rare aggressive dual primary tumors AFPGC and SCLC, demonstrating significant long-term maintenance benefits from the immunotherapy. Concurrently, this case confirmed the efficacy and safety of tislelizumab during the maintenance therapy phase for both tumors, offering a new treatment option for managing such complex clinical presentations.
Keywords: AFPGC, SCLC, case report, immunotherapy, tislelizumab
Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, People’s Republic of China
Correspondence: Tong Zhang, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1, Xiyuan Playground, Haidian District, Beijing, 100091, People’s Republic of China, Tel +86-010-62835438, Email ashtray7654@126.com
Background: Alpha-fetoprotein-positive gastric cancer (AFPGC) is a rare subtype of gastric cancer characterized by high invasiveness and extremely poor prognosis. According to relevant studies, the median overall survival of such patients is significantly shorter than that of AFP-negative gastric cancer patients (14 months vs 40 months). Small cell lung cancer (SCLC), the most malignant type of lung cancer, has a median survival time of only 8– 12 months in patients with extensive disease. To date, there have been no reported cases of dual primary cancers involving both AFPGC and SCLC, and the therapeutic role of immunotherapy in such dual primary tumors remains unclear.
Case Presentation: This paper reports a case of a 72-year-old male patient who was diagnosed via imaging and pathology as having concurrent AFPGC (moderately to poorly differentiated adenocarcinoma, PD-L1 positive, Tumor mutation burden(TMB) 10.03Muts/Mb, PD-L1 Combined Positive Score (CPS)< 1) combined with primary extensive-stage SCLC. The patient received CAPEOX regimen (capecitabine plus oxaliplatin) combined with tislelizumab therapy. After 4 cycles, partial response (PR) was observed in the gastric lymph nodes, and stable disease (SD) was noted in the pulmonary lesions. Following pathological confirmation of dual primary cancers, treatment continued with the original regimen, followed by maintenance therapy with tegafur gimeracil oteracil potassium capsule (teysuno) plus tislelizumab. During treatment, serum AFP levels decreased from baseline 502 μg/L to 1.56 μg/L. Both primary tumor lesions remained stably controlled for over 33 months, and the patient currently tolerates treatment well with an Eastern Cooperative Oncology Group (ECOG) performance status of 0.
Conclusion: Through the long-term treatment course of this case, we validated the therapeutic efficacy of chemotherapy combined with immunotherapy (CAPEOX plus tislelizumab) for the rare aggressive dual primary tumors AFPGC and SCLC, demonstrating significant long-term maintenance benefits from the immunotherapy. Concurrently, this case confirmed the efficacy and safety of tislelizumab during the maintenance therapy phase for both tumors, offering a new treatment option for managing such complex clinical presentations.
Keywords: AFPGC, SCLC, case report, immunotherapy, tislelizumab